Navigation Links
Cytopia Lodges IND for JAK2 Inhibitor CYT387
Date:6/22/2009

MELBOURNE, Australia, June 22 /PRNewswire/ -- Cytopia Ltd (ASX: CYT) announced today that it has filed an Investigational New Drug Application (IND) with the US Food and Drug Administration (FDA) for its novel, potent orally active JAK2 inhibitor CYT387.

Following FDA review, the company intends to commence a Phase I/II trial for CYT387 in patients with myelofibrosis, a serious progressive and chronic condition where scar tissue develops in the bone marrow. CYT387 is expected to be the second Cytopia developed drug candidate in clinical studies and the first trialled in the United States, with the anticancer

vascular disrupting agent CYT997 now in Phase II clinical studies in Australia.

Over-activity of the JAK2 enzyme is implicated in a variety of haematological conditions known as the myeloproliferative disorders (MPDs). This suite of conditions includes myelofibrosis, polycythemia vera and essential thrombocythemia. Cytopia has demonstrated that CYT387 inhibits the overactive JAK2 enzyme in an invivo preclinical model and in cells from patients with MPDs. This data suggests that the compound may exert a profound effect on the human disease.

Myelofibrosis results in a compromised ability of patients to produce sufficient blood cells and a reliance on organs other than the bone marrow, including the liver and spleen, to produce cells. Typical symptoms include an enlarged spleen and progressive anemia and poor overall survival.

"The filing of an IND for CYT387 is the culmination of a comprehensive preclinical development effort by the Cytopia Drug Development team," said Mr Andrew Macdonald, CEO of Cytopia. "Our deep knowledge of the JAK2 target has been integral to the design of this drug and the program is significantly bolstered by the intellectual property we hold over the JAK2 target."

The clinical utility of CYT387 is also expected to have broader applicability
'/>"/>

SOURCE Cytopia Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Cytopia To Present Data on FMS Program With Anticancer Potential
2. Cytopia Commences Phase II Cancer Drug Study
3. Potent metastasis inhibitor identified
4. Small molecule inhibitor shows promise in trastuzumab-resistant metastatic breast cancer
5. Cylene to Announce New Data on Its First-in-Class Oral CK2 Inhibitor Against Cancer at BIO Conference
6. For the Treatment of Rheumatoid Arthritis, Market Share for TNF-alpha Inhibitors Will Decrease Through 2018
7. Video: Novartis Receives Approval From FDA to Market Prevacid(R) 24HR as First and Only OTC Proton Pump Inhibitor in Original Prescription Formulation
8. SCAI Statement on A National Study of the Effect of Individual Proton Pump Inhibitors on Cardiovascular Outcomes in Patients Treated with Clopidogrel Following Coronary Stenting: The Clopidogrel Medco Outcomes Study
9. Alseres and BioAxone Amend License Agreement for Cethrin(R) and Rho Inhibitor Technology
10. Potential lung disease biomarkers yield clues to COX-2 inhibitor side effects
11. Experimental insulin-like growth factor receptor inhibitor reduced pancreatic cancer growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... September 18, 2014 First Choice ... emergency rooms in the United States, named Douglas J. ... Missouri City-Lakes facility. , “We are pleased to ... medical director of our new Missouri City-Lakes facility,” said ... Choice Emergency Room. , Dr. Harrison received his ...
(Date:9/18/2014)... 9Lover.com, an internationally well-known designer and leader in the ... for its maternity wedding outfits. Now, all the company’s ... wedding dresses on its website. , 9Lover.com ... The company’s development manager believes the cheap maternity wedding ... current special offer will last until September 29, 2014. ...
(Date:9/17/2014)... ball gown is the most formal female attire for ... the floor, made of luxurious fabric, delicately and exotically ... and retailer, has delightedly unveiled its new series of ... at discounted rates. , Most versions are cut off ... worn with a stole (a formal shawl in expensive ...
(Date:9/17/2014)... D.C. (PRWEB) September 18, 2014 The ... in the Match , a comprehensive analysis of the ... to a preferred specialty. The new edition is ... data by specialty for U.S. allopathic medical school senior ... delighted to be able to provide this new edition ...
(Date:9/17/2014)... Creek, MI (PRWEB) September 17, 2014 ... , an open-ended drug and alcohol treatment program that ... them a solid foundation in recovery they can believe ... depression. , “About 20% of Americans who are afflicted ... both,” commented A Forever Recovery’s CEO Per Wickstrom ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Announces Dr. Douglas J. Harrison as Medical Director of Missouri City - Lakes, Texas Facility 2Health News:Discounted Maternity Wedding Dresses For 2014 Introduced By 9Lover.com 2Health News:Fecbek.com: Ladies Can Be Elegant Enough to Draw Everyone’s Attention by Wearing Trendy Ball Gowns 2Health News:Just Released: Charting Outcomes in the Match for the 2014 Main Residency Match® 2Health News:Just Released: Charting Outcomes in the Match for the 2014 Main Residency Match® 3Health News:Latest A Forever Recovery Blog Post Explores the Link Between Addiction and Depression 2Health News:Latest A Forever Recovery Blog Post Explores the Link Between Addiction and Depression 3
... BRAUNFELS, Texas, Feb. 5 The following,release was issued ... 59, car crash victim and ten-year resident at the,Eden ... Store EVP of Operations, Dan Gibbens, The SCOOTER ... Store Gift of Mobility Administrator, Betty Doeppenschmidt, of ...
... Outsources Billing, Accounts Receivable Services, BIRMINGHAM, ... Practice Services unit has completed an agreement ... Paramedical Services,one of the largest medical transport ... and software for billing and accounts,receivable management., ...
... Pa., Feb. 5 West Pharmaceutical,Services, Inc. (NYSE: ... Chairman and Chief Executive Officer, and William Federici, Chief,Financial ... Healthcare,Services Conference at 3:00 p.m. on February 11, 2008 ... corporate presentation document will be posted on the,investor link ...
... ... to LYFT, PALM SPRINGS, Calif., Feb. 5 ... its 12th Annual Winter,Symposium in Palm Springs, Calif. The meeting, which will ... using,high-risk donors, will open with a discussion of the proposed organ,allocation system ...
... 5 /PRNewswire-FirstCall/ - CRH Medical Corporation,(CRM:TSX-V) announced today ... had,13,461 patient visits at its Centers for Colorectal ... period in 2006., Commenting on this achievement, ... 2007, we demonstrated the strong demand for the ...
... 10:00am EST Today, LENEXA, Kan., Feb. 5 ... of ClosedLoop(TM) clinical systems,for blood and medication management, reported ... of $8,659,000 compared to $11,262,000 in the,comparable quarter in ... or a loss of four cents per fully diluted ...
Cached Medicine News:Health News:Regional Paramedical Services and DST Health Solutions Complete Business Process Outsourcing Agreement 2Health News:West Pharmaceutical Services to Present at the 2008 UBS Global Healthcare Services Conference 2Health News:AST to Address New Concept in Organ Allocation at March 13-16 Winter Symposium 2Health News:CRH Medical Corporation announces substantial increase in patient visits 2Health News:Mediware Reports Second Quarter Fiscal 2008 Results 2Health News:Mediware Reports Second Quarter Fiscal 2008 Results 3Health News:Mediware Reports Second Quarter Fiscal 2008 Results 4
(Date:9/17/2014)... NEW YORK , Sept. 17, 2014 /PRNewswire/ ... Summary GlobalData,s new report, "Germany ... market data on the Germany Gynecological Devices market. ... dollars, volume (in units) and average prices (in ... Devices (Transcervical Sterilization Devices (Micro-inserts) and Mechanical Sterilization ...
(Date:9/17/2014)... SANTA MONICA, Calif. , Sept. 17, 2014 /PRNewswire-USNewswire/ ... who is at the White House today for National ... Proposition 46 that consumer advocates released today. Consumer advocates ... woman who spoke out after losing her ... later discovering that the doctor had a history of ...
(Date:9/17/2014)... , Sept. 17, 2014  Decision ... colitis (CD/UC) patients eligible for biologic therapy, ... a biologic. Surveyed gastroenterologists cite patients, discomfort ... for low penetration rates, followed by cost-related ... UC patients receiving biologics, Janssen Biotech,s Remicade ...
Breaking Medicine Technology:Germany Gynecological Devices Market Outlook to 2020 2Germany Gynecological Devices Market Outlook to 2020 3Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 2Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 3The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 2The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 3
... OncoSec Medical Incorporated (OTCBB:ONCS), which is developing ... to treat solid tumor cancers, today announced that ... and Lakeland Comprehensive Cancer Center in Lakeland, FL ... are screening patients for the Phase II metastatic ...
... International, Inc. (NASDAQ: BDSI ) announced that ... of further litigation in the patent infringement lawsuit previously ... that the case would be stayed pending resolution by ... proceedings and follows the recent rejection by the USPTO ...
Cached Medicine Technology:OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial 2OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial 3OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial 4Federal Court Grants Request by BioDelivery Sciences for Stay of MonoSol Litigation 2Federal Court Grants Request by BioDelivery Sciences for Stay of MonoSol Litigation 3